Concepedia

Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric <scp>Multiple Sclerosis</scp>

Kristen M. Krysko, Jennifer Graves, Mary Rensel, Bianca Weinstock‐Guttman, Alice Rutatangwa, Gregory Aaen, Anita Belman, Leslie Benson, Tanuja Chitnis, Mark Gorman,

Annals of Neurology · 2020 · 107 citations · 36 references

DOI

Abstract

Initial treatment of pediatric MS/CIS with newer DMTs led to better disease activity control compared to injectables, supporting greater effectiveness of newer therapies. Long-term safety data for newer DMTs are required. ANN NEUROL 2020 ANN NEUROL 2020;88:42-55.

References

36

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.7K citations · Full text

, , +15

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Jeffrey A. Cohen, Frederik Barkhof, Hans‐Peter Hartung et al. · New England Journal of Medicine · 2010 · 2.2K citations · Full text

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Richard A. Rudick, William H. Stuart, Peter A. Calabresi et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions

Lauren Krupp, Marc Tardieu, Maria Pia Amato et al. · Multiple Sclerosis Journal · 2013 · 1.1K citations